<http://schema.org/description>
"The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2014-03-darapladib-falls-short-chronic-coronary.html>